Thanks! I bought some KNSA on the assumption that the stock is priced a little low even without the Covid angle. A press release announcing a new government-funded Covid study would be gravy. Big Pharma could even buy mavrilimumab. The GM-CSF trial news is still new information that is undoubtedly being discussed behind the scenes. I'll hold on to KNSA for awhile to see if anything materializes. With the KNSA's stock price not rising on last Thursday's FDA approval for pericarditis, my guess is that news will at least prevent the stock price from falling much.
News 
Market Data 
Discover 
